newsfilter
← Latest News
GlobeNewswire·

Clearmind Medicine Announces Hong Kong Patent Filing for Depression Therapy

  • Clearmind Medicine Inc. filed a patent application in Hong Kong for a non-hallucinogenic combination therapy targeting major depressive disorder.
  • The innovative treatment blends the company's proprietary 5-methoxy-2-aminoindane (MEAI) with Palmitoylethanolamide (PEA).
  • Palmitoylethanolamide is sourced through a partnership with NeuroThera Labs Inc., a subsidiary of SciSparc Ltd.
  • The therapy aims to address a global market for depression affecting over 332 million people, with the overall market expected to exceed $25 billion by 2030.
  • The MEAI-PEA synergy is positioned as a safer, more accessible, & affordable alternative to existing antidepressants such as SSRIs.
  • Clearmind Medicine holds 31 granted patents across 19 patent families & intends to seek additional intellectual property protection.
  • The company's shares trade on the Nasdaq under the symbol "CMND".